DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
250 Marquette Ave, Ste. 600 Minneapolis, MN 55401 (612)334-4100 Fax:(612)334-4134	3/9/2026-3/12/2026
	FEI NUMBER 3015401429

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED
Erik C. Lazarich, President

FIRM NAME	STREET ADDRESS
Milla Pharmaceuticals, Inc.	1310 Highway 96E Suite 104A
CITY, STATE, ZIP CODE, COUNTRY White Bear Lake, MN 55110-3618	TYPE ESTABLISHMENT INSPECTED ANDA sponsor

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

OBSERVATION 1

Written procedures have not been developed for the of post marketing adverse drug experiences.

Specifically, procedures for vendor qualification and auditing have not been followed concerning the PV vendor, initially contracted in 11/2021, with no initial qualification, annual reassessment, or contract-required audit each 2 years.

AMENDMENT 1

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE	DATE ISSUED
	Sharon L Matson, Investigator X Sharon L Matson Investigator Signed By: SHARON L. MATSON -S Date Signed: 03-13-2026 08:50:17	3/13/2026

The observations of objectionable conditions and practices listed on the front of this form are reported:

1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or
2. To assist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration.

Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides:

"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."